Prescription Digital Therapeutics, or PDTs, are software-based disease treatments. PDTs are designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. PDTs are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software.
The leader in Prescription Digital Therapeutics
At Pear, our mission is clear: we are pioneers in PDTs. Our cross-functional team operates at the intersection of biology and software technology. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
Multiple products, therapeutic areas, and development stages
We are developing prescription digital therapeutics, or PDTs, to treat patients suffering from a range of serious diseases. Pear’s lead product, reSET®, for the treatment of Substance Use Disorder, and was the first PDT to receive authorization from FDA to improve disease outcomes. Pear’s second product, reSET-O® for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation and was authorized in December 2018. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program and was authorized in March 2020. Our pipeline is focused on product candidates across therapeutic areas to address unmet medical needs and demonstrate clinically relevant treatment effects.